Back to results
US 2026/0124285 A1Published application
Personalized cancer vaccines
AssigneeModernaTX, Inc.
InventorsMichelle Brown, Igor Feldman, Robert Meehan, Celine Robert-Tissot, Wei Zheng
Life of this patent
Estimating the term…
Abstract
Personalized mRNA cancer vaccines, as well as methods for their optimization and for their use in subjects are provided. In some embodiments, personalized mRNA cancer vaccines and their uses are provided for subjects having particular characteristics, e.g., the presence of certain biomarkers.
Claims28
A method of inducing an immune response against a tumor in a subject, the method comprising:
- (a) administering to a subject an effective amount of an immune checkpoint inhibitor;
- (b) measuring one or more biomarkers or biomarker levels in a biological sample collected from the subject, wherein the measuring is conducted before or on the day of the administering of (c);
- and
- (c) administering to the subject an effective amount of a personalized cancer vaccine, wherein the measurement of the one or more biomarkers or biomarker levels identifies the subject as likely to be responsive to the personalized cancer vaccine, and wherein the personalized cancer vaccine comprises:
- (i) an mRNA comprising an open reading frame that encodes at least two cancer antigen epitopes expressed in the tumor in the subject;
- and
- (ii) a lipid delivery vehicle,
- wherein the administration of the immune checkpoint inhibitor and the personalized cancer vaccine induces an immune response against the tumor in the subject.
5 more elements
(canceled)
7-11. (canceled)
(canceled)
(canceled)
(canceled)
A method of inducing an immune response against a tumor in a subject, the method comprising:
- (a) administering to a subject an effective amount of an immune checkpoint inhibitor;
- (b) administering to the subject an effective amount of a first personalized cancer vaccine, comprising:
- an mRNA comprising an open reading frame that encodes at least two cancer antigen epitopes expressed in the tumor in the subject, and a lipid delivery vehicle;
- (c) measuring one or more biomarkers or biomarker levels in a biological sample collected from the subject, wherein the measuring is conducted after the administering of (b);
- and
- (d) administering to the subject an effective amount of a second personalized cancer vaccine, comprising:
- an mRNA comprising an open reading frame that encodes at least two cancer antigen epitopes expressed in the tumor in the subject;
- and a lipid delivery vehicle;
- wherein the measurement of the one or more biomarkers or biomarker levels identifies the subject as likely to be responsive to the second personalized cancer vaccine,
- wherein the administration of the immune checkpoint inhibitor and the first and second personalized cancer vaccine induces an immune response against the tumor in the subject.
7 more elements
(canceled)
Dependencies are inferred from the claim text.